Strs Ohio trimmed its position in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 46.9% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 6,900 shares of the biotechnology company’s stock after selling 6,100 shares during the period. Strs Ohio’s holdings in Prothena were worth $332,000 as […]
Penserra Capital Management LLC bought a new position in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,104 shares of the biotechnology company’s stock, valued at approximately $211,000. Several other […]
E Fund Management Co. Ltd. decreased its position in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 20.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,427 shares of the biotechnology company’s stock after selling 1,622 shares during the period. E […]
Prothena (NASDAQ:PRTA – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Monday. PRTA has been the topic of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $129.00 target price on shares of Prothena […]
Prothena (NASDAQ:PRTA – Get Free Report) had its target price lowered by JMP Securities from $83.00 to $81.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price target indicates a potential upside of 115.71% from the stock’s previous close. […]